Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![SquawkCNBC Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::404422077.png) Squawk Box [@SquawkCNBC](/creator/twitter/SquawkCNBC) on x 513.2K followers
Created: 2025-06-23 14:37:52 UTC

.@GileadSciences CEO Daniel O'Day joins to discuss the FDA approval of the company's new HIV prevention medication, Yetzugo.

![](https://pbs.twimg.com/card_img/1937157780047007744/X6yVhDd9?format=jpg&name=800x419)

XXXXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1937158166485119325/c:line.svg)

**Related Topics**
[gilead sciences](/topic/gilead-sciences)
[stocks healthcare](/topic/stocks-healthcare)

[Post Link](https://x.com/SquawkCNBC/status/1937158166485119325)

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

SquawkCNBC Avatar Squawk Box @SquawkCNBC on x 513.2K followers Created: 2025-06-23 14:37:52 UTC

.@GileadSciences CEO Daniel O'Day joins to discuss the FDA approval of the company's new HIV prevention medication, Yetzugo.

XXXXX engagements

Engagements Line Chart

Related Topics gilead sciences stocks healthcare

Post Link

post/tweet::1937158166485119325
/post/tweet::1937158166485119325